Aging is characterized by clonal expansion of myeloid-biased hematopoietic stem cells and by increased risk of myeloid malignancies. Exome sequencing of three elderly females with clonal hematopoiesis, demonstrated by X-inactivation analysis, identified somatic TET2 mutations. Recurrence testing identified TET2 mutations in 10 out of 182 individuals with X-inactivation skewing. TET2 mutations were specific to individuals with clonal hematopoiesis without hematological malignancies and were associated with alterations in DNA methylation.
The aging hematopoietic system is characterized by an altered hemato poietic stem cell (HSC) compartment that exhibits myeloid lineage bias and increased incidence of myeloid malignancies 1, 2 . Normally, the fraction of cells with inactivation of each X chromosome in female mammalian cells is equivalent, and deviation from the 1:1 Xchromosome inactivation ratio is referred to as skewing. Previous studies measuring Xinactivation ratios in females identi fied ageassociated skewing (AAS) in blood cells, particularly within the myeloid compartment 3, 4 . One of several postulated causes of AAS is the acquisition of somatic mutation(s) that confer growth advan tage and result in clonal hematopoiesis 5 . Recent studies in mice have led investigators to hypothesize that agerelated myeloid lineage bias can be explained by clonal expansion of HSCs that are intrinsically biased toward the myeloid lineage 1,2 . However, a genetic basis for this phenomenon has not been elucidated, nor have recurrent somatic mutations been observed in individuals with clonal hematopoiesis without clinically apparent hematopoietic malignancies.
We hypothesized that somatic genetic abnormalities occur in the normal aging population and are a key cause of AAS in the myeloid compartment. We performed exome sequencing of polymorpho nuclear cells (PMNs) and buccal epithelial cells from three elderly individuals with AAS (Supplementary Fig. 1a) . In one subject, we identified somatic mutations in TET2, DNMT3A, SLC39A12, ERCC6 and KIAA1919 (Supplementary Table 1 ). We did not identify vali dated somatic mutations in the other two individuals with median exome sequencing coverage of 110×. Notably, the TET2 mutation was a nonsense mutation, analogous to the inactivating TET2 muta tions observed in individuals with myeloid malignancies (Fig. 1a and Supplementary Fig. 1b) 6 .
To determine whether mutations in these genes recur in subjects with AAS, we performed resequencing of all 5 genes mutated in the index subject in 284 healthy, elderly women aged >65 years (179 with Xinactivation skewing, 105 without skewing) and 96 younger women aged <60 years (all with Xinactivation skewing). We identi fied missense, nonsense and frameshift somatic TET2 mutations, which were present in granulocyte DNA but not in lymphocyte or buccal DNA, in 10 out of 182 (5.6%) of the elderly subjects with AAS, in 0 out of 105 of the elderly subjects without AAS and in 0 out of 96 of the younger subjects with AAS, suggesting that TET2 mutations are highly enriched in elderly subjects with AAS (P < 0.007; linear logistic) ( Table 1) . Additional somatic mutations in DNMT3A, SLC39A12, ERCC6 and KIAA1919 were not observed (Supplementary Table 2 ). Each TET2 mutation was easily detectable as a dominant TET2mutant PMN clone ( Supplementary Fig. 1b,c) , and, in each case, Xinactivation patterns at the AR locus (also known as HUMARA) in PMNs further confirmed that TET2mutant individ uals had fully skewed X inactivation consistent with clonally derived hematopoiesis (Supplementary Methods). Measures of TET2 mutant allele burden by highcoverage nextgeneration sequencing in indi viduals with TET2 mutations were highly concordant with the degree of skewing identified by the HUMARA assay in the majority of the subjects studied (Supplementary Table 3 Fig. 2 and Supplementary Table 4) . Notably, we obtained clinical followup information for seven of the TET2mutant subjects for 5 years or longer after mutational analysis. Although six individuals remained without clinical evidence of a hematological malignancy, one TET2 mutant subject subsequently presented with JAK2 V617F-positive essential thrombocytosis. The increased prevalence of TET2 muta tions in older individuals with hematological cancers 11 and the age dependence of TET2 mutations in our cohort of elderly subjects further support the idea of an initiating role for TET2 mutation in the pathogenesis of ageassociated hematological cancers.
The TET2 protein catalyzes the hydroxylation of 5methylcytosine (5mC) throughout the mammalian genome, resulting in loss of DNA methylation 12 . Consonant with these functional data, we have previ ously shown that TET2mutant individuals with acute myeloid leuke mia (AML) are characterized by a hypermethylation phenotype with sitespecific cytosine methylation of target genes. Quantitative mass spectrometry measurement of 5hydroxymethylcytosine (5hmC) and 5mC levels revealed that TET2mutant elderly individuals with acquired clonal hematopoiesis (n = 6) had reduced 5hmC levels com pared with younger individuals with skewed Xinactivation ratios (n = 10) and increased 5mC levels compared with younger clonal individuals or agematched polyclonal controls (n = 15) (Fig. 1b) . We also observed a decrease in global 5hmC levels in myeloid cells with age, suggesting that decreases in 5hmC may be an important feature in the aging hematopoietic system, with acquired TET2 mutations being one mechanism underlying these decreases. To determine whether the global changes in 5mC and/or 5hmC were associated with sitespecific changes in promoter methylation, we performed quantitative DNA methylation analysis of loci known to be hypermethylated in indi viduals with AML who have TET2 mutations 13 . This analysis revealed significant focal increases in sitespecific promoter methylation in elderly subjects with TET2 mutations (seven individuals with TET2 mutations and seven agematched controls with wildtype TET2), which were associated with transcriptional silencing of these target genes (n = 3 genes) (Fig. 1c) .
Here, we report somatic, recurrent TET2 mutations in normal elderly individuals with acquired clonal hematopoiesis. These data, in combination with recent mouse studies, support a model in b r i e f c o m m u n i c a t i o n s which TET2 mutation in HSCs confers enhanced selfrenewal and clonal expansion, resulting in agerelated myeloid lineage bias. More broadly, we report the existence of clonal somatic mutations in the hematopoietic compartment of normal individuals without overt hematopoietic malignancies. The potential contribution of such mutations to risk of oncogenic transformation must be determined prospectively in larger cohorts of aging individuals, and further studies will likely identify additional somatic mutations that cause clonal hematopoiesis and predispose to the development of hema tological malignancies.
Note: Supplementary information is available in the online version of the paper.
